Clinical Trials Logo

Clinical Trial Summary

Prospective single-centre, observational study with medical products. Patients with a medical history of SVT will be observed for at least 24 months after inclusion. The study will begin when the patient is referred to our centre for SVT and will end at the 24-month follow-up or at the occurrence of a study outcome event, or in case of Death OBJECTIVE: To prospectively define the incidence of recurrent thrombosis and bleeding events during anticoagulant therapy in patients with diagnosed SVT, regardless of whether they will be hospitalized or treated as outpatients


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06262750
Study type Observational
Source Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Contact valerio de stefano
Phone +390630154206
Email valerio.destefano@unicatt.it
Status Recruiting
Phase
Start date December 1, 2023
Completion date November 1, 2025

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04994158 - MASCOT Registry of Patients With Myeloproliferative Neoplasms Associated Splanchnic Vein Thrombosis
Recruiting NCT03778502 - DOAC in Unusual Site Venous Thrombosis
Active, not recruiting NCT04631458 - Outcomes in Patients With Myeloproliferative Neoplasm and Splanchnic Vein Thrombosis
Recruiting NCT06390475 - Optimizing Diagnosis of Splanchic Vein Thrombosis With MRDTI (Rhea)
Active, not recruiting NCT03080883 - Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy Phase 3